Effect of spirulina in treatment of polycystic ovary syndrome

Phase 2

Conditions: Polycystic ovary syndrome.
Polycystic ovarian syndrome
E28.2

Registration Number: IRCT20230122057180N1

Lead Sponsor: Kashan University of Medical Sciences

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Pending

Sex: Female

Target Recruitment: 60

Inclusion Criteria

Patients with polycystic ovary syndrome according to Rotterdam criteria
Women aged 25-40 years
Complete informed consent

Exclusion Criteria

Hyperprolactinemia
Thyroid disorders
Subjects following a special diet or consuming drugs with an effect on hormonal profile like oral conceptives (OCP)
Steroid hormones, or any other drugs probably to affect ovarian action in the last 3 months
Type 2 diabetes mellitus (T2DM)
Cushing’s syndrome
Smokers
Unwillingness to cooperate

Study & Design

Study Type: interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Fasting plasma glucose. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Clinical symptoms. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Questionnaire PCOS (Based on NIH criteria).

Secondary Outcome Measures

Name	Time	Method
Total cholesterol. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 12 weeks of intervention. Method of measurement: Enzymatic kit.